...
首页> 外文期刊>Stem cells translational medicine. >Human Mesenchymal Stromal Cells: Identifying Assays to Predict Potency for Therapeutic Selection
【24h】

Human Mesenchymal Stromal Cells: Identifying Assays to Predict Potency for Therapeutic Selection

机译:人间质基质细胞:鉴定试验,以预测治疗选择的效能。

获取原文
           

摘要

Multipotent mesenchymal stromal cells (MSCs) have the potential to repair and regenerate damaged tissues, making them attractive candidates for cell-based therapies. To maximize efficacy of MSCs, prediction of their therapeutic abilities must be made so that only the best cells will be used. Our goal was to identify feasible and reproducible in vitro assays to predict MSC potency. We generated cell lines from 10 normal human bone marrow samples and used the International Society for Cellular Therapy's minimal criteria to define them as MSCs: plastic adherence, appropriate surface marker expression, and trilineage differentiation. Each MSC line was further characterized by its growth, proliferation, and viability as determined by cell count, bromodeoxyuridine incorporation, and cellular ATP levels, respectively. To determine whether these tests reliably predict the therapeutic aptitude of the MSCs, several lines were implanted in vivo to examine their capacity to engraft and form granulation tissue in a well-established murine wound model using polyvinyl alcohol sponges. Long-term engraftment of MSCs in the sponges was quantified through the presence of the human-specific Alu gene in sponge sections. Sections were also stained for proliferating cells, vascularity, and granulation tissue formation to determine successful engraftment and repair. We found that high performance in a combination of the in vitro tests accurately predicted which lines functioned well in vivo. These findings suggest that reliable and reproducible in vitro assays may be used to measure the functional potential of MSCs for therapeutic use.
机译:多能间质基质细胞(MSC)具有修复和再生受损组织的潜力,使其成为基于细胞疗法的有吸引力的候选者。为了最大程度地发挥MSC的功效,必须预测其治疗能力,以便仅使用最佳细胞。我们的目标是确定可行且可重复的体外测定方法,以预测MSC的效力。我们从10个正常人骨髓样本中生成了细胞系,并使用国际细胞疗法学会的最低标准将它们定义为MSC:塑料粘附,适当的表面标志物表达和三系分化。通过分别由细胞计数,溴脱氧尿苷掺入和细胞ATP水平确定的其生长,增殖和生存力来进一步表征每个MSC系。为了确定这些测试是否能够可靠地预测MSC的治疗能力,在体内建立了几行品系,以检查它们在使用聚乙烯醇海绵建立的成熟小鼠伤口模型中植入并形成肉芽组织的能力。通过海绵切片中人类特异性Alu基因的存在,可以定量地将MSC长期植入海绵中。还对切片进行染色以检测增殖细胞,血管和肉芽组织的形成,以确定成功的植入和修复。我们发现,结合体外测试的高性能可准确预测哪些品系在体内功能良好。这些发现表明,可靠且可再现的体外测定法可用于测量MSC在治疗方面的功能潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号